Oral Zavegepant Shows Favorable Tolerability in Terminated Chronic Migraine Prevention Trial
A multicenter phase 2/3 trial found that once-daily oral zavegepant demonstrated favorable safety and tolerability up to 200 milligrams daily ...
A multicenter phase 2/3 trial found that once-daily oral zavegepant demonstrated favorable safety and tolerability up to 200 milligrams daily ...
We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.
Bioengineer.org © Copyright 2023 All Rights Reserved.
Bioengineer.org © Copyright 2023 All Rights Reserved.